Accuracy of an urine-based liquid biopsy genetic test in detecting renal pelvic cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e16500-e16500
Author(s):  
Yansheng Xu ◽  
Min Shi ◽  
Yiming Liang ◽  
Hongzhao Li ◽  
Xin Ma ◽  
...  
Keyword(s):  
High Risk ◽  
Renal Pelvis ◽  
Liquid Biopsy ◽  
Genetic Test ◽  
Methylation Status ◽  
Pathology Report ◽  
Low Grade ◽  
Tumor Implantation ◽  
Pelvic Cancer ◽  
Renal Pelvic Cancer

e16500 Background: Renal pelvis cancer is accounting for about two-thirds of upper tract urinary carcinoma. Lesions in renal pelvis often lead to a differential diagnosis that requires ureteroscopic biopsy. Besides causing discomfort and pain, ureteroscopy prior to surgery increases risk of tumor implantation and recurrence. Although urine cytology and FISH were applied, more effective non-invasive diagnostic method is imperative for diagnosis of renal pelvic cancer. Methods: A total of 141 patients with one or more lesions in renal pelvis detected by ultrasound were enrolled. 50-ml first-void urine sample was collection before ureteroscopic biopsy and was analysis by Genetron uro-18 genes panel, by which mutations in 17 genes and methylation status of ONECUT2 were analysis using high-throughput sequencing. If mutations and/or ONECUT2 methylation were detected in urine sediment DNA, the patients were considered as high risk of renal pelvis cancer. The results of the urine-based liquid biopsy genetic test were compared with pathology report and urine FISH results of urinary cells. Results: According to pathological analysis with ureteroscopic biopsy, 42 out of 141 patients (29.7%) were diagnosis with renal pelvic cancer: 13 low-grade, 24 high-grade, 5 equivocal. For 33 renal pelvic cancer patients with FISH testing result of urinary cells, only 54.5% (18/33) samples were positive. By Genetron uro-18 genes test, 95 patients (67.4%) were classified as high risk and 46 (32.6%) patients were low risk. The overall specificity was 88.0% (88/95) and overall sensitivity was 92.9% (39/42), which is significant higher than FISH test of urinary cells. Conclusions: With high specificity and sensitivity, Genetron uro-18 genes test could be incorporated in renal pelvic cancer diagnosis, especially for patients with a ultrasound detectable lesions. Ureteroscopy prior to surgery could be reduced, which may lead to decrease risk of tumor implantation and recurrence.

scholarly journals AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION

2013 ◽  
Vol 55 (5) ◽  
pp. 329-334 ◽  
Author(s):  
Fernanda Nahoum Carestiato ◽  
Larissa Alves Afonso ◽  
Natalia Moyses ◽  
Gutemberg Leao Almeida Filho ◽  
Luis Guillermo Coca Velarde ◽  
...  
Keyword(s):  
High Risk ◽  
Methylation Status ◽  
Hpv Infection ◽  
Cross Sectional Study ◽  
Methylation Pattern ◽  
Low Grade ◽  
Tobacco Exposure ◽  
Upward Trend ◽  
Cross Sectional ◽  
Risk Of Cancer

SUMMARY High-risk human papillomavirus (hr-HPV) infection is necessary but not sufficient for cervical cancer development. Recently, P16INK4A gene silencing through hypermethylation has been proposed as an important cofactor in cervical carcinogenesis due to its tumor suppressor function. We aimed to investigate P16INK4A methylation status in normal and neoplastic epithelia and evaluate an association with HPV infection and genotype. This cross-sectional study was performed with 141 cervical samples from patients attending Hospital Moncorvo Filho, Rio de Janeiro. HPV detection and genotyping were performed through PCR and P16INK4A methylation by nested-methylation specific PCR (MSP). HPV frequency was 62.4% (88/141). The most common HPV were HPV16 (37%), HPV18 (16.3%) and HPV33/45(15.2%). An upward trend was observed concerning P16INK4A methylation and lesion degree: normal epithelia (10.7%), low grade lesions (22.9%), high grade (57.1%) and carcinoma (93.1%) (p < 0.0001). A multivariate analysis was performed to evaluate an association between methylation, age, tobacco exposure, HPV infection and genotyping. A correlation was found concerning methylation with HPV infection (p < 0.0001), hr-HPV (p = 0.01), HSIL (p < 0.0007) and malignant lesions (p < 0.0001). Since viral infection and epigenetic alterations are related to cervical carcinoma, we suggest that P16INK4A methylation profile maybe thoroughly investigated as a biomarker to identify patients at risk of cancer.

Chinese Herb Resveratrol Inhibits Renal Pelvic Cancer Cell Proliferation via Regulating miR-30a-5p

2021 ◽  
Vol 15 (2) ◽  
pp. 253-259
Author(s):  
Zunwei Zhu ◽  
Jinggong Wu ◽  
Lieyu Xu ◽  
Yong Wan ◽  
Haichao Chao ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Cell Proliferation ◽  
Cell Survival ◽  
Renal Pelvis ◽  
Cell Apoptosis ◽  
Target Gene ◽  
Chinese Herb ◽  
Cancer Cell Proliferation ◽  
Pelvic Cancer ◽  
Renal Pelvic Cancer

Renal pelvis cancer (RPC) is rare with unclear pathogenesis. Resveratrol (RSV) also plays a beneficial role in preventing chronic diseases related to inflammation. But its effect on RPC cells has not been reported. RPC cells were cultured and treated with resveratrol for 48 hours followed by analysis of cell proliferation, apoptosis and cell cycle, and miR-30a-5p expression. The expression of miR-30a-5p effects proliferation, apoptosis and cell cycle was also assessed. After treatment, RPC cells showed upregulated miR-30a-5p, decreased cell survival and enhanced cell apoptosis rate compared with abnormal cell cycle (P < 0.05), and the effect was more significant with the increase in concentration (P < 0.05). The miR-30a-5p target gene is AVEN. miR-30a-5p downregulation can reverse its effect on RPC cells (P < 0.05). Resveratrol treatment on RPC cells can upregulate miR-30a-5p, inhibite cell proliferation, promotes apoptosis, and changes cell cycle.

scholarly journals A Case of Renal Pelvic Cancer with a Complete Duplication of the Renal Pelvis and Ureter

2021 ◽  
pp. 202-206
Author(s):  
Takuma Nirei ◽  
Tadashi Tabei ◽  
Hiroki Ito ◽  
Kazuki Kobayashi
Keyword(s):  
Renal Pelvis ◽  
Histopathological Examination ◽  
Upper Urinary Tract ◽  
Magnetic Resonance Imaging Scan ◽  
Ectopic Ureter ◽  
Gross Hematuria ◽  
Pelvic Cancer ◽  
Renal Pelvic Cancer ◽  
Enhanced Computed Tomography ◽  
Complete Duplication

This paper describes a case of renal pelvic cancer with a complete duplication of the renal pelvis and ureter, which is substantially rare. A 76-year-old man was referred to the hospital because of gross hematuria for 2 years. A tumor was detected in the upper right kidney using enhanced computed tomography and magnetic resonance imaging scan, and the downstream ureter was suspected to open into the prostate. Retrograde ureteroscopy via the ectopic ureter orifice showed a hemorrhagic papillary tumor consistent with imaging findings. Laparoscopic radical nephroureterectomy was performed and the prostate was preserved because the tumor was only in the renal pelvis. Histopathological examination showed the tumor as a high-grade urothelial carcinoma. There was no sign of recurrence at one and a half years after operation. Ureteroscopy was effective in detecting an upper urinary tract tumor, even via ectopic ureter orifice, and preserving the prostate was possible.

Endourological treatment of large neoplasm in the lower tract of the ureter

1992 ◽  
Vol 59 (1_suppl) ◽  
pp. 104-107
Author(s):  
V. Gramegna ◽  
S. Capizzi ◽  
D. Spalmero ◽  
A. Madaro ◽  
O. Romano ◽  
...  
Keyword(s):  
Transitional Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Pelvis ◽  
Personal Experience ◽  
Transitional Cell ◽  
Low Grade

Conservative endourological treatment of transitional cell carcinoma of renal pelvis and ureter is controversial. The treatment should be reserved for selected cases and for low grade, low stage, monofocal tumors. Personal experience with endourological treatment of a transitional cell carcinoma of the lower tract of the ureter is presented.

scholarly journals TissueCypher Barrett’s esophagus assay impacts clinical decisions in the management of patients with Barrett’s esophagus

2021 ◽  
Vol 09 (03) ◽  
pp. E348-E355
Author(s):  
David L. Diehl ◽  
Harshit S. Khara ◽  
Nasir Akhtar ◽  
Rebecca J. Critchley-Thorne
Keyword(s):  
High Risk ◽  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Clinical Decision Making ◽  
Eradication Therapy ◽  
Low Risk ◽  
Management Approach ◽  
Low Grade ◽  
Management Decisions ◽  
The Impact

Abstract Background and study aims The TissueCypher Barrett’s Esophagus Assay is a novel tissue biomarker test, and has been validated to predict progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s esophagus (BE). The aim of this study was to evaluate the impact of TissueCypher on clinical decision-making in the management of BE. Patients and methods TissueCypher was ordered for 60 patients with non-dysplastic (ND, n = 18) BE, indefinite for dysplasia (IND, n = 25), and low-grade dysplasia (LGD, n = 17). TissueCypher reports a risk class (low, intermediate or high) for progression to HGD or EAC within 5 years. The impact of the test results on BE management decisions was assessed. Results Fifty-two of 60 patients were male, mean age 65.2 ± 11.8, and 43 of 60 had long segment BE. TissueCypher results impacted 55.0 % of management decisions. In 21.7 % of patients, the test upstaged the management approach, resulting in endoscopic eradication therapy (EET) or shorter surveillance interval. The test downstaged the management approach in 33.4 % of patients, leading to surveillance rather than EET. In the subset of patients whose management plan was changed, upstaging was associated with a high-risk TissueCypher result, and downstaging was associated with a low-risk result (P < 0.0001). Conclusions TissueCypher was used as an adjunct to support a surveillance-only approach in 33.4 % of patients. Upstaging occurred in 21.7 % of patients, leading to therapeutic intervention or increased surveillance. These results indicate that the TissueCypher test may enable physicians to target EET for TissueCypher high-risk BE patients, while reducing unnecessary procedures in TissueCypher low-risk patients.

scholarly journals RTID-05. INDIGO: A GLOBAL, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF VORASIDENIB (AG-881) VS PLACEBO IN PATIENTS WITH RESIDUAL/RECURRENT GRADE II GLIOMA WITH AN ISOCITRATE DEHYDROGENASE 1/2 (IDH1/2) MUTATION

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii194-ii194
Author(s):  
Ingo Mellinghoff ◽  
Martin van den Bent ◽  
Jennifer Clarke ◽  
Elizabeth Maher ◽  
Katherine Peters ◽  
...  
Keyword(s):  
High Risk ◽  
Dose Escalation ◽  
Objective Response ◽  
Data Monitoring Committee ◽  
Progression Free Survival ◽  
High Risk Population ◽  
Low Grade ◽  
Who Grade ◽  
Free Survival ◽  
Grade Ii

Abstract BACKGROUND Low-grade gliomas (LGGs; WHO grade II) are incurable and ultimately progress to high-grade gliomas. The current treatment options are surgery followed by observation (“watch and wait”) for patients with lower risk for disease progression or postoperative chemoradiotherapy (high-risk population). There are no approved targeted therapies. IDH1 and IDH2 mutations (mIDH1/2) occur in approximately 80% and 4% of LGGs, respectively, and promote tumorigenesis via neomorphic production of D-2-hydroxyglutarate. Vorasidenib, an oral, potent, reversible, brain-penetrant pan-inhibitor of mIDH1/2, was evaluated in 76 patients with glioma in two phase 1 studies (dose escalation and perioperative) and was associated with a favorable safety profile at daily doses below 100 mg. Preliminary clinical activity was observed in non-enhancing glioma patients in both studies, with an objective response rate (ORR) of 18.2% and median progression-free survival of 31.4 months in the dose escalation study. METHODS Approximately 366 patients will be randomized 1:1 to vorasidenib (50 mg QD) or matched placebo and stratified by 1p19q status (intact vs co-deleted). Key eligibility criteria: age ≥ 12 years; grade II oligodendroglioma or astrocytoma (per WHO 2016 criteria) not in need of immediate treatment and without high-risk features; centrally confirmed mIDH1/2 status; ≥ 1 surgery for glioma with most recent ≥ 1 year but ≤ 5 years before randomization, and no other anticancer therapy; Karnofsky performance status ≥ 80%; and centrally confirmed measurable, non-enhancing disease evaluable by magnetic resonance imaging. Crossover from placebo to the vorasidenib arm is permitted upon centrally confirmed radiographic progression per RANO-LGG criteria. Primary endpoint: progression-free survival assessed by independent review. Secondary endpoints: safety and tolerability, tumor growth rate assessed by volume, ORR, overall survival, and quality of life. Clinical data will be reviewed regularly by an independent data monitoring committee. The study is currently enrolling patients in the US, with additional countries planned (NCT04164901).

Renal pelvic cancer: A review of 611 patients treated in Illinois 1975–1985

Urology ◽  
1992 ◽  
Vol 40 (5) ◽  
pp. 393-399 ◽  
Author(s):  
Patrick Guinan ◽  
Nicholas J. Vogelzang ◽  
Randal Randazzo ◽  
Stephen Sener ◽  
Joan Chmiel ◽  
...  
Keyword(s):  
Pelvic Cancer ◽  
Renal Pelvic Cancer
Sign in / Sign up

Export Citation Format

Share Document